Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval

Executive Summary

Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.

You may also be interested in...



Acne Claims For Cosmetics Leave Blemish On UK Advertising Regs

Advertising Standards Authority issued decisions Oct. 17 on complaints against three cosmetics brands and an online beauty retailer for statements the independent regulator reads as acne-treatment claims, or the “spots” equivalent, calling them medicinal claims for unlicensed products.

Acne Claims For Cosmetics Leave Blemish On UK Advertising Regs

Advertising Standards Authority issued decisions Oct. 17 on complaints against three cosmetics brands and an online beauty retailer for statements the independent regulator reads as acne-treatment claims, or the “spots” equivalent, calling them medicinal claims for unlicensed products.

Cough/Cold, Analgesic Patch Sales Ease Pain Of Private Label Growth In OTCs

Topical analgesic sales grew double digits in 2017 on innovation and adhesive patch launches, helping drive 2.1% growth of US manufacturers' OTC drug sales in 2017 to $21.2bn, Kline & Co. independent consultant Laura Mahecha says. But private label continues to outpace branded product sales growth.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel